Ayala Pharmaceuticals, Inc.
ADXSHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $13,000 | $250,000 | $3.2M | $253,000 | $20.9M | $6.1M |
| Operating income | −$36.3M | −$37.5M | −$18.8M | −$26.4M | −$18.0M | −$70.4M |
| Net income | −$48.1M | −$38.0M | −$17.9M | −$26.5M | −$16.6M | −$66.5M |
| Total assets | $16.6M | $7.8M | $46.8M | $38.5M | $45.3M | $62.3M |
| Total liabilities | — | $2.3M | $7.9M | $8.3M | $5.7M | $38.2M |
| Equity | −$24.4M | −$1.1M | $34.2M | $30.2M | $39.5M | $24.1M |
| EPS (diluted) | $-7.99 | $-13.13 | $-11.07 | — | — | — |
| Shares out. | 4.8M | 145.6M | 112.0M | 78.1M | 50.2M | 69.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −278969.2%
- Net margin
- −369784.6%
- Return on equity
- 196.9%
- Return on assets
- −290.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-5.05
- Revenue growth (YoY)
- −94.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Accruals / assets
- −112.1%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 15, 2023
- NT 10-Kmissed a reporting deadline ↗Jan 30, 2023
- NT 10-Kmissed a reporting deadline ↗Jan 31, 2022
- NT 10-Qmissed a reporting deadline ↗Mar 18, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jan 30, 2026 | 23 | 1.0 | 0.0% |
| Jan 15, 2026 | 23 | 1.0 | 0.0% |
| Dec 31, 2025 | 23 | 1.0 | 0.0% |
| Dec 15, 2025 | 23 | 1.0 | 0.0% |
| Nov 28, 2025 | 23 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 3, 2024
- Completed an acquisition or disposition · Unregistered equity sale · Regulation FD disclosureMar 29, 2024
- Entered a material agreement · New financial obligationMar 5, 2024
- Director / officer changeFeb 23, 2024
- Unregistered equity sale · Shareholder voteFeb 9, 2024
- Entered a material agreement · Director / officer change · Regulation FD disclosureFeb 6, 2024
- Completed an acquisition or disposition · Unregistered equity sale · Director / officer changeOct 20, 2023
- Entered a material agreement · Unregistered equity saleSep 21, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.